SPORANOX CAPSULE

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ITRACONAZOLE

から入手可能:

JANSSEN INC

ATCコード:

J02AC02

INN（国際名）:

ITRACONAZOLE

投薬量:

100MG

医薬品形態:

CAPSULE

構図:

ITRACONAZOLE 100MG

投与経路:

ORAL

パッケージ内のユニット:

28/30

処方タイプ:

Prescription

治療領域:

AZOLES

製品概要:

Active ingredient group (AIG) number: 0123311002; AHFS:

認証ステータス:

APPROVED

承認日:

2002-06-03

製品の特徴

_Non Ann PM SNDS SPOC 275453 09052023.docx _
_ _
_EDMS-RIM-1034546 v4.0 _
_ _
_ _
_Page 1 of 55_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SPORANOX
®
itraconazole
capsules, 100 mg, oral
Antimycotic for systemic use, triazole and tetrazole derivatives
ATC code: J02A C02
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen.com/canada
Date of Initial Authorization:
August 17, 1993
Date of Revision:
October 3, 2023
Control Number: 275453
All trademarks used under license.
© 2023 Janssen Inc.
_Non Ann PM SNDS SPOC 275453 09052023.docx _
_ _
_EDMS-RIM-1034546 v4.0 _
_ _
_ _
_Page 2 of 55_
RECENT MAJOR LABEL CHANGES
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES .................................................................................
2
TABLE OF CONTENTS .....................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION ........................................................... 4
1
INDICATIONS ........................................................................................................
4
1.1
Pediatrics
................................................................................................
4
1.2
Geriatrics
.................................................................................................
4
2
CONTRAINDICATIONS ..........................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX ................................................... 6
4
DOSAGE AND ADMINISTRATION ..........................................................................
7
4.1
Dosing Considerations
..............................................................................
7
4.2
Recommended Dose and Dosage Adjustment
............................................ 7
4.4
Administration
.................................................................